TATVA - Tatva Chintan
📢 Recent Corporate Announcements
Tatva Chintan Pharma Chem has been notified of a mandatory 20% reduction in natural gas supply following the 'Natural Gas (Supply Regulation) Order, 2026.' The government mandate, triggered by geopolitical conflicts in the Middle East, limits industrial supply to 80% of the past six months' average consumption. Furthermore, gas pricing will now be governed by a Pooled Price mechanism, which may lead to higher input costs. While the company is utilizing alternative fuels and optimizing processes, the full financial impact is currently unquantified.
- Natural gas supply capped at 80% of the average consumption of the previous six months.
- Pricing shifted to a Pooled Price mechanism notified by the Petroleum Planning & Analysis Cell (PPAC).
- Government mandate issued under the Essential Commodities Act, 1955, superseding existing gas contracts.
- Company proactively adopting alternative fuel sources permitted by the Gujarat Pollution Control Board.
- Order classified as a Force Majeure mitigation measure due to Middle East supply disruptions.
Tatva Chintan Pharma Chem Limited has informed the exchanges of a scheduled interaction with Emerge Capital. The meeting is set for March 18, 2026, and will be conducted in a virtual one-on-one format. The company has explicitly stated that only publicly available information will be discussed, ensuring no unpublished price sensitive information (UPSI) is shared. This is a standard regulatory disclosure under SEBI (LODR) Regulations, 2015, aimed at maintaining investor relations.
- One-on-one virtual meeting scheduled with Emerge Capital for March 18, 2026.
- Interaction is part of routine investor engagement under SEBI Regulation 30.
- Company confirms that no confidential or UPSI will be shared during the session.
- The schedule is subject to change depending on investor or company availability.
Tatva Chintan Pharma Chem Limited has scheduled a virtual one-on-one meeting with Ask Wealth Advisor Private Limited for March 16, 2026. This interaction is part of the company's routine investor relations activities to discuss business performance using publicly available data. The company has clarified that no unpublished price sensitive information (UPSI) will be shared during the session. Such meetings indicate ongoing institutional interest in the company's specialty chemical business.
- One-on-one virtual meeting scheduled with Ask Wealth Advisor Private Limited on March 16, 2026.
- Interaction will be based strictly on publicly available information as per SEBI regulations.
- No confidential or unpublished price sensitive information (UPSI) will be disclosed during the meeting.
- The meeting schedule is subject to change based on exigencies from either side.
Tatva Chintan Pharma Chem Limited has scheduled a one-on-one virtual meeting with ABN Capital Asset Managers LLP on February 16, 2026. This interaction is part of the company's routine investor relations activities to discuss publicly available information. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during this session. Such meetings are standard practice for listed entities to maintain transparency with institutional investors.
- One-on-one virtual meeting scheduled for February 16, 2026.
- Interaction is with ABN Capital Asset Managers LLP.
- Compliant with Regulation 30 of SEBI (LODR) Regulations, 2015.
- Discussions will be limited to publicly available information only.
Tatva Chintan Pharma Chem Limited has submitted a formal disclosure under Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The filing pertains to transactions involving the purchase and sale of company securities by insiders, as reported to the company on February 09, 2026. While the specific volume of shares was not detailed in the cover letter, these disclosures are mandatory for maintaining transparency regarding promoter and management holdings. Investors typically monitor these filings to gauge the sentiment of internal stakeholders.
- Compliance filing under Regulation 7(2)(b) of SEBI (Prohibition of Insider Trading) Regulations
- Disclosure includes information received from both a Seller and a Purchaser
- Official notification submitted to BSE and NSE on February 09, 2026
- Standard regulatory procedure for reporting changes in insider shareholding
Ajay Mansukhlal Patel, a promoter of Tatva Chintan Pharma Chem, has disclosed a proposed acquisition of 7,15,345 equity shares, representing a 3.06% stake in the company. This transaction is an inter-se off-market transfer resulting from the dissolution and full partition of the Ajay Mansukhlal Patel (HUF). As this is a distribution of family assets for succession planning, there is no monetary consideration involved. The total promoter group holding remains unchanged, reflecting only an internal restructuring of shares.
- Proposed acquisition of 7,15,345 equity shares (3.06% stake) by promoter Ajay Mansukhlal Patel.
- Transfer is being executed from Ajay Mansukhlal Patel (HUF) due to its dissolution and full partition.
- The transaction is an off-market inter-se transfer with NIL monetary consideration.
- Ajay Mansukhlal Patel's individual shareholding will increase from 17.10% to 20.16% post-transaction.
- The acquisition is scheduled to take place on or after February 06, 2026.
Tatva Chintan reported a robust Q3 FY26 with operating revenue reaching ₹1,313 million, a 53% YoY increase, driven by a massive 86% growth in the Pharma & Agro segment. EBITDA witnessed a significant surge of 261% YoY to ₹255 million, reflecting improved operational efficiencies and a recovery in Structured Directing Agents (SDA). The company is set to break ground on a new greenfield facility at Jolva this quarter, focusing on high-value agro-intermediate import substitutes. Management indicated that validation trials for new capacities are scheduled to begin in mid-February 2026.
- Operating revenue grew 53% YoY to ₹1,313 million, with a 6% sequential improvement.
- EBITDA increased by 261% YoY to ₹255 million, showing strong margin recovery and operational leverage.
- Pharma, Agro & Specialty Chemicals segment revenue surged 86% YoY to ₹471 million.
- Structured Directing Agents (SDA) revenue grew 65% YoY to ₹534 million despite a 10% sequential dip.
- New greenfield project at Jolva, Dahej, to break ground in Q4 FY26 for agro-intermediate import substitution.
Tatva Chintan Pharma Chem Limited has officially released the audio recording of its earnings conference call held on January 21, 2026. The call took place at 5:00 p.m. IST following the company's latest financial disclosures. This release is in compliance with SEBI Listing Obligations and Disclosure Requirements to ensure transparency for all stakeholders. Investors can now access the management's commentary and Q&A session via the provided web link.
- Earnings call conducted on Wednesday, January 21, 2026, at 05:00 p.m. IST
- Audio recording link made available on the official company website for public access
- Compliance with Regulation 46(2)(oa) of SEBI (LODR) Regulations, 2015
- Recording provides direct access to management's discussion on financial performance
Tatva Chintan reported a robust financial recovery in Q3 FY26, with consolidated revenue growing 53% YoY to ₹1,313 million. Profitability saw a massive turnaround as PAT reached ₹152 million compared to a nominal ₹1 million in the same quarter last year. EBITDA margins expanded significantly to 19% from 8% YoY, driven by improved operational efficiencies and a favorable product mix. The Structure Directing Agents (SDA) segment continues to lead growth, contributing 41% to the total revenue for the nine-month period.
- Consolidated Revenue for Q3 FY26 grew 53% YoY to ₹1,313 million, while 9M FY26 revenue rose 35% to ₹3,717 million.
- EBITDA (excluding other income) for Q3 FY26 jumped 261% YoY to ₹255 million with margins improving to 19%.
- Net Profit (PAT) for 9M FY26 stands at ₹317 million, a 578% increase compared to ₹47 million in 9M FY25.
- Structure Directing Agents (SDA) segment remains the largest revenue contributor at 41%, followed by PASC at 34%.
- Balance sheet remains strong with a low Debt-to-Equity ratio of 0.11x as of H1 FY26.
Tatva Chintan reported a strong performance for Q3 FY26, with consolidated revenue from operations growing 53% YoY to ₹1,313.34 million. The company achieved a significant turnaround in profitability, posting a net profit of ₹151.65 million compared to just ₹1.38 million in the same quarter last year. On a nine-month basis, the net profit reached ₹317.33 million, a substantial jump from ₹46.83 million in 9M FY25. This growth was supported by a recovery in the specialty chemicals segment and improved operational efficiencies.
- Consolidated Revenue from operations increased 52.9% YoY to ₹1,313.34 million.
- Net Profit witnessed a massive surge to ₹151.65 million from ₹1.38 million in Q3 FY25.
- Profit Before Tax (PBT) turned positive at ₹176.58 million versus a loss of ₹2.35 million YoY.
- 9M FY26 Revenue grew to ₹3,717.04 million, up from ₹2,748.50 million in the previous year.
- Earnings Per Share (EPS) for the quarter stood at ₹6.48, compared to ₹0.06 in the year-ago period.
Tatva Chintan Pharma Chem Limited has scheduled its earnings conference call for the quarter and nine months ended December 31, 2025. The call is set for Wednesday, January 21, 2026, at 5:00 PM IST and will be hosted by ICICI Securities. Senior management, including Managing Director Chintan Shah and CFO Ajesh Pillai, will be present to discuss financial results. This call provides a platform for investors to gain clarity on the company's performance and future growth strategy.
- Earnings call for Q3 and 9M FY26 scheduled for January 21, 2026, at 17:00 IST.
- Management representation includes MD Chintan Shah and CFO Ajesh Pillai.
- The conference call is hosted by ICICI Securities with Diamond Pass registration available.
- The call follows the announcement of financial results for the period ended December 31, 2025.
Tatva Chintan Pharma Chem Limited has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the period ended December 31, 2025. The certificate, issued by MUFG Intime India Private Limited, confirms that all dematerialization requests were processed and confirmed to the depositories within the prescribed timelines. It also verifies that the security certificates were mutilated and cancelled after verification, with the depositories' names updated in the register of members. This is a standard procedural filing required for all listed entities in India.
- Compliance certificate submitted for the quarter ended December 31, 2025.
- Confirmation provided by Registrar and Share Transfer Agent, MUFG Intime India Private Limited.
- Adherence to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 confirmed.
- Verification that dematerialized securities are listed on the stock exchanges where earlier securities were listed.
Tatva Chintan Pharma Chem Limited has announced the closure of its trading window starting January 1, 2026, in compliance with SEBI Insider Trading regulations. This closure is ahead of the announcement of the company's unaudited financial results for the quarter and nine months ending December 31, 2025. The restriction applies to all designated persons and their immediate relatives. The window will reopen 48 hours after the results are officially declared to the exchanges.
- Trading window closure effective from January 1, 2026
- Relates to financial results for the quarter and nine months ending December 31, 2025
- Applies to all Designated Persons and their immediate relatives
- Window reopens 48 hours after the declaration of financial results
Financial Performance
Revenue Growth by Segment
Consolidated revenue for FY25 was INR 385.03 Cr, reflecting a 3.99% YoY decline. The SDA (Structure Directing Agents) segment, a high-margin business, recorded sales of INR 119.72 Cr. However, H1FY26 showed a recovery with revenue reaching INR 240.4 Cr, a 27% increase compared to INR 189.0 Cr in H1FY25.
Geographic Revenue Split
Exports accounted for 61.53% of revenue (INR 235.47 Cr) in FY25, down from 70.36% (INR 276.86 Cr) in FY24. Domestic sales increased to 38.47% (INR 144.43 Cr) from 28.88% (INR 113.63 Cr) in the previous year, indicating a shift toward the Indian market amidst global demand volatility.
Profitability Margins
Standalone Profit After Tax (PAT) margin plummeted to 1.56% (INR 5.71 Cr) in FY25 from 8.01% (INR 30.35 Cr) in FY24. This 81.18% decline in PAT was driven by lower sales in the high-margin SDA segment and increased competition.
EBITDA Margin
EBITDA margin for H1FY26 improved to 16.0% from 10.0% in H1FY25, a 600 bps increase. Historical operating margins have fluctuated between 9.49% and 26% over the last five years due to raw material price volatility.
Capital Expenditure
The company made a net addition of INR 76.13 Cr to fixed assets in FY25. Total R&D-related CAPEX for the fiscal year was INR 8.43 Cr, aimed at strengthening the product pipeline for emerging opportunities.
Credit Rating & Borrowing
CRISIL reaffirmed the 'CRISIL A-' rating with a 'Stable' outlook (upgraded from Negative). Interest coverage ratio remains high at 28.3 times, and bank limit utilization is low at 5.33%, indicating strong debt-servicing capability.
Operational Drivers
Raw Materials
Primary raw materials are crude oil derivatives, which are highly susceptible to global price fluctuations. These materials constitute a significant portion of the cost structure, with operating margins swinging by over 16% historically based on procurement costs.
Import Sources
Sourced from diverse geographies across 30+ countries to mitigate localized supply disruptions. The company utilizes its wholly-owned subsidiaries, Tatva Chintan USA Inc. and Tatva Chintan Europe B.V., to manage international logistics and sourcing.
Capacity Expansion
Current aggregate manufacturing capacity stands at 280 KL with 13 assembly lines, following an expansion from 160 KL and 10 assembly lines. The company operates facilities in Ankleshwar (Zero Liquid Discharge) and Dahej SEZ.
Raw Material Costs
Raw material costs are a major component of the INR 221.97 Cr cost of materials consumed in FY25. Profitability is highly sensitive to these costs, as seen in the moderation of margins when SDA segment sales (which use specific high-value inputs) decline.
Manufacturing Efficiency
The company utilizes integrated and fungible manufacturing facilities, allowing for production flexibility across different product categories like SDAs and PTCs based on market demand.
Logistics & Distribution
Debtors turnover ratio declined to 4.60 in FY25 from 5.59 in FY24, primarily due to higher sales in Q4 FY25, resulting in year-end receivables of approximately 79 days.
Strategic Growth
Expected Growth Rate
27%
Growth Strategy
Growth will be driven by the commercialization of new products in FY26, leveraging the expanded 280 KL capacity, and increasing domestic market penetration (which grew 27% in FY25). The company is also focusing on high-value R&D products for the Pharma and Agrochemical sectors.
Products & Services
Structure Directing Agents (SDAs), Phase Transfer Catalysts (PTCs), Electrolyte Salts for supercapacitor batteries, and specialty chemicals for Pharma, Agrochemicals, Dyes, and Paints.
Brand Portfolio
Tatva Chintan
New Products/Services
The company is entering the commercial phase of new products in FY26, which are expected to be crucial for improving the business risk profile and margin recovery.
Market Expansion
Targeting expansion in over 30 countries with a focus on increasing the share of domestic sales, which rose to INR 144.43 Cr in FY25.
Strategic Alliances
Maintains wholly-owned subsidiaries in the USA (Tatva Chintan USA Inc.) and Europe (Tatva Chintan Europe B.V.) to act as marketing and distribution arms.
External Factors
Industry Trends
The specialty chemical industry is seeing a shift toward sustainable 'green' chemistry. Tatva Chintan is positioned for this through its 'zero liquid effluent discharge' facility and R&D focus on high-value, sustainable products.
Competitive Landscape
Faces increased competition in the SDA segment, which pressured margins in FY25, though it remains a leading player in the niche specialty chemicals space.
Competitive Moat
The moat is built on in-house R&D capabilities, fungible manufacturing lines, and deep-rooted relationships with global marquee clients. Sustainability is supported by the high entry barriers in the SDA and PTC segments.
Macro Economic Sensitivity
Highly sensitive to global economic slowdowns, which can plummet revenues across end-user sectors like Pharma, Agrochemicals, and Paints.
Consumer Behavior
Shift toward high-performance electronics and green energy is driving demand for the company's electrolyte salts used in supercapacitor batteries.
Geopolitical Risks
Widespread geographical presence in 30+ countries exposes the company to diverse regulatory changes and trade barriers, managed through stringent compliance with international ISO standards.
Regulatory & Governance
Industry Regulations
Complies with stringent manufacturing standards and drug manufacturing licenses from the Food and Drugs Control Administration, Gujarat.
Environmental Compliance
Maintains Zero Liquid Effluent Discharge at the Ankleshwar facility and holds ISO 14001:2015 certification for environmental management.
Taxation Policy Impact
The effective tax rate for FY25 was approximately 24.6%, with total tax expenses of INR 1.87 Cr on a Standalone Profit Before Tax of INR 7.58 Cr.
Legal Contingencies
The company has disclosed pending litigations in Note 46 of its financial statements; however, it does not anticipate material foreseeable losses from long-term or derivative contracts.
Risk Analysis
Key Uncertainties
The primary uncertainty is the timing of the demand recovery in the SDA segment, which could impact cash accruals if they fall below INR 2.5 Cr per month.
Geographic Concentration Risk
61.53% of revenue is concentrated in international markets, making the company vulnerable to global trade cycles and shipping disruptions.
Third Party Dependencies
Dependency on suppliers for crude oil derivatives is a risk, mitigated by maintaining diverse sourcing across different geographies.
Technology Obsolescence Risk
Mitigated by continuous R&D investment (INR 12.83 Cr in FY25) to ensure the product pipeline remains relevant for evolving customer preferences.
Credit & Counterparty Risk
Receivables are monitored closely, though debtor days increased due to high Q4 sales, with a year-end debtor balance reflecting a turnover ratio of 4.60.